携手共赢丨广东省人民医院吴一龙教授团队代表性论著阶段汇总
读书笔记丨感恩并传承CTONG-中国肺癌原创临床研究
CTONG-TALK | 带你走进CTONG的世界
CTONG-TALK｜CTONG 1509研究开启EGFR突变NSCLC联合治疗新模式
CTONG-TALK｜CTONG 1103——讲述新辅助靶向治疗的故事
读书笔记丨历届肺癌高峰论坛专家共识汇总
传承与发展丨长三角肺癌代表性论著阶段汇总
走进中国科学院大学附属肿瘤医院（浙江省肿瘤医院）I期临床试验病房
Lung Cancer A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer Yi-long Wu (2002)
Chin J Med Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial Yi-long Wu (2007)
Lancet Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Yi-long Wu (2008)
N Engl J Med Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma Yi-long Wu (2009)
Lancet Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Yi-long Wu (2009)
J Clin Oncol Randomized, placebo-controlled, phase II study of sequential Erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer Yi-long Wu (2009)
Lancet Oncol Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study Yi-long Wu (2009)
J Clin Oncol Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-celllung cancer in Asia (IPASS) Yi-long Wu (2009)
J Thorac Oncol Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) Yi-long Wu (2011)
Lancet Oncol Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Yi-long Wu (2011)
BMC Cancer INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer Yi-long Wu (2011)
J Thorac Oncol Safety and efficacy of first-line Bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC results from the phase IV MO19390 (SAiL) study Yi-long Wu (2011)
Lung Cancer Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study Yi-long Wu (2011)
Lung Cancer Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study Yi-long Wu (2012)
J Thorac Oncol Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial Yi-long Wu (2012)
Chin J Cancer Res Nedaplatin/Gemcitabine versus Carboplatin/Gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial Yi-long Wu (2012)
Asia-Pacific J Clin Oncol Phase III, randomized, open-label, first-line study in Asia of gefitinib versuscar boplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from China Yi-long Wu (2012)
Chin J Cancer Res Nedaplatin/Gemcitabine versus Carboplatin/Gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial Yi-long Wu (2012)
N Engl J Med Crizotinib versus chemotherapy in advanced ALK-positive lung cancer Yi-long Wu (2013)
Ann Oncol Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and a symptomatic brain metastases: a phase II study (CTONG-0803) Yi-long Wu (2013)
Lancet Oncol Icotinib versus gefitinib inpreviously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Yi-long Wu (2013)
Lancet Oncol Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Yi-long Wu (2013)
Lung Cancer Tumor response and health-related quality oflife in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line
gefitinib: Post hoc analyses from the IPASS study Yi-long Wu (2013)
Lung Cancer A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805) Yi-long Wu (2013)
BMC Cancer A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung Yi-long Wu (2013)
Lancet Oncol Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi-long Wu (2014)
Lung Cancer Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer Yi-long Wu (2014)
Lung Cancer Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS) Yi-long Wu (2014)
N Engl J Med First-line Crizotinib versus chemotherapy in ALK-positive lung cancer Yi-long Wu (2014)
Ann Oncol Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial Yi-long Wu (2014)
Lancet Oncol Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Yi-long Wu (2014)
J Clin Oncol BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line Carboplatin/Paclitaxelplus Bevacizumab or Placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer Yi-long Wu (2014)
Lancet Oncol Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Yi-long Wu (2014)
Lancet Oncol Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefi tinib (IMPRESS): a phase 3 randomised trial Yi-long Wu (2014)
J Clin Oncol Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04 Yi-long Wu (2015)
J Hematol Oncol Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status Yi-long Wu (2015)
Ann Oncol Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Yi-long Wu (2015)
Ann Oncol First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study Yi-long Wu (2015)
J Thorac Oncol Symptom and quality of life improvementin LUX-Lung 6: An open-label phase III study of Afatinib versus Cisplatin/Gemcitabine in Asian patients with EGFR mutation-positive advanced non-small cell lung cancer Yi-long Wu (2015)
J Thorac Oncol Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial A phase III, multicenter, placebo-controlled trial of Sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens Yi-long Wu (2015)
Clin Cancer Res Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated Erlotinib and chemotherapy Yi-long Wu (2015)
J Hematol Oncol Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial Yi-long Wu (2016)
Lung Cancer A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (Currents) Yi-long Wu (2016)
Lung Cancer Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinumin the first-line treatment of advanced non-small-cell lung cancer Yi-long Wu (2016)
Asia-Pacific J Clin Oncol An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin oretoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer Yi-long Wu (2016)
J Thorac Oncol First-line Afatinib versus chemotherapy in patients with non-small cell lung cancer and common Epidermal Growth Factor Receptor gene mutations and brain metastases Yi-long Wu (2016)
Ann Oncol Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Yi-long Wu (2016)
Lancet Respir Med Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial Yi-long Wu (2016)
J Clin Oncol Intracranial efficacy of Crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014 Yi-long Wu (2016)
Lung Cancer Maintenance erlotinib versus erlotinib atdisease progression inpatients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study) Yi-long Wu (2016)
J Clin Oncol Phase III randomized trial of Ipilimumab plus Etoposide and Platinum versus Placebo plus Etoposide and Platinum in extensive-stage small-cell lung cancer Yi-long Wu (2016)
Lung Cancer Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinumin the first-line treatment of advanced non-small-cell lung cancer Yi-long Wu (2016)
Br J Cancer A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations Yi-long Wu (2016)
Lancet Oncol Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi-long Wu (2016)
Br J Cancer EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 Yi-long Wu (2016)
Lancet First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study Yi-long Wu (2016)
Lung Cancer Efficacy according to blind independent central review: post-hoc analyses from the Phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC Yi-long Wu (2017)
J Clin Oncol Gefitinib plus chemotherapy versus chemotherapy in Epidermal Growth Factor Receptor mutation-positive non-small-celllung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses Yi-long Wu (2017)
Lancet First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study Yi-long Wu (2017)
N Engl J Med Osimertinib or platinum-pemetrexedin EGFR T790M-positive lung cancer Yi-long Wu (2017)
J Clin Oncol CNS efficacy of Osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: Data from a randomized phase III trial (AURA3) Yi-long Wu (2018)
Lancet Respir Med Detection of EGFR mutations in plasma circulating tumor DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial Yi-long Wu (2018)
J Clin Oncol Final overall survival analysis from a study comparing first-line Crizotinib with chemotherapy: Results from PROFILE 1014 Yi-long Wu (2018)
Lancet Oncol Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Yi-long Wu (2018)
J Clin Oncol Improvement in overall survival in a randomized study that compared Dacomitinib with Gefitinib in patients with advanced non-small-cell lung cancer and EGFR activating mutations Yi-long Wu (2018)
J Clin Oncol Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor therapy in patients with EGFR-mutated, MET Factor-Dysregulated non-small-cell lung cancer Yi-long Wu (2018)
J Clin Oncol Phase II study of Crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer Yi-long Wu (2018)
J Thorac Oncol Results of PROFILE 1029, a phase III comparison of first-line Crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer Yi-long Wu (2018)
J Thorac Oncol The unique spatial-temporal treatment failure patterns of adjuvant Gefitinib Therapy: A Post Hoc analysis of the ADJUVANT Trial (CTONG 1104) Yi-long Wu (2018)
Eur J Cancer A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002) Yi-long Wu (2018)
Lung Cancer Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies Yi-long Wu (2018)
Lung Cancer Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial Yi-long Wu (2018)
Lung Cancer EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer Yi-long Wu (2018)
Clin Lung Cancer ADAURA: Phase III, double-blind, randomized study of Osimertinib versus Placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection Yi-long Wu (2018)
Clin Lung Cancer Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials Yi-long Wu (2018)
Patient Does EGFR mutation type influence patient-reported outcomes in patients with advanced EGFR mutation-positive non-small-cell lung cancer? Analysis of two large, phase III studies comparing Afatinib with chemotherapy (LUX-Lung 3 and LUX-Lung 6) Yi-long Wu (2018)
Onco Targets Ther Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial Yi-long Wu (2018)
EBioMedicine Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosinekinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial Yi-long Wu (2019)
Am J Clin Oncol Efficacy and safety of Gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with First-line Gefitinib followed by second-line chemotherapy A single-arm, prospective, multicenter phase II study (RE-CHALLENGE, CTONG1304) Yi-long Wu (2019)
Lung Cancer First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials Yi-long Wu (2019)
Lung Cancer Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies Yi-long Wu (2019)
J Clin Oncol Erlotinib versus Gemcitabine plus Cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-celllung cancer (EMERGING-CTONG 1103): A randomized phase II study Yi-long Wu (2019)
J Thorac Oncol Nivolumab versus Docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial Yi-long Wu (2019)
Lancet Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Yi-long Wu (2019)
Lung Cancer Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study Yi-long Wu (2019)
Lung Cancer Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib：Results from ASCEND-6 Yi-long Wu (2020)
N Engl J Med Osimertinib in resected EGFR-mutated non-small-cell lung cancer Yi-long Wu (2020)
Lancet Respir Med Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial Yi-long Wu (2020)
Invest New Drugs A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer Yi-long Wu (2020)
J Clin Oncol Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutat NSCLC: Final overall survival analysis of CTONG1104 phase III trial Yi-long Wu (2020)
Ann Oncol Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small cell lung cancer：an open-label，randomized，multicenter，phase III trial Yi-long Wu (2020)
Cancer Epidermal Growth Factor Receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus Platinum-Pemetrexed for T790M mutation-positive advanced non-small cell lung cancer Yi-long Wu (2020)
Lung cancer Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA （N1-N2）EGFR-mutat non-small-cell lung cancer：Results from the ADJUVANT （CTONG 1104）study Yi-long Wu (2020)
Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Yi-long Wu (2020)
Int J Cancer Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study Yi-long Wu (2020)
Future Oncol The patient's perspective on treatment with dacomitinib：patient-reported outcomes from the phase III trial ARCHER 1050 Yi-long Wu (2020)
Anticancer Res Phase I study of the Pan-PI3K Inhibitor Buparlisib in adult Chinese patients with advanced solid tumors Yi-long Wu (2016)
Lancet Oncol COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Yi-long Wu (2020)
J Immunother Cancer Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study Yi-long Wu (2020)
J Thorac Oncol Epidermal Growth Factor Receptor mutations and their correlation with Gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in China Yi-long Wu (2007)
Cancer Lett Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals Yi-long Wu (2008)
Mol Cancer Fusion of EML4 and ALK is associated with development of lung adenocarcinom as lacking EGFR and KRAS mutations and is correlated with ALK expression Yi-long Wu (2010)
J Hematol Oncol RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy Yi-long Wu (2010)
Eur J Cancer CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1(CA)n polymorphism Yi-long Wu (2010)
J Hematol Oncol Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib Yi-long Wu (2011)
J Clin Oncol Relative abundance of EGFR mutations predicts benefit from Gefitinib treatment for advanced non-small-cell lung cancer Yi-long Wu (2011)
J Thorac Oncol A clinical model to estimate the pretest probability of lung cancer, based on 1198 pedigrees in China Yi-long Wu (2012)
J Hematol Oncol Can EGFR-TKIs be used infirst line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? –A literature-based meta-analysis Yi-long Wu (2012)
Oncologist EGFR mutation heterogeneity and the mixed response to EGFR Tyrosine Kinase Inhibitors of lung adenocarcinomas Yi-long Wu (2012)
Mol Cancer BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification Yi-long Wu (2013)
Clin Cancer Res Lung cancers with concomitant EGFR mutations and ALK rearrangements: Diverse responses to EGFR-TKI and Crizotinib in relation to diverse receptors phosphorylation Yi-long Wu (2014)
J Thorac Oncol MET expression plays differing roles in non-small-cell lung cancer patients with or without EGFR mutation Yi-long Wu (2014)
Clin Cancer Res Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line Intercalated Erlotinib and chemotherapy Yi-long Wu (2015)
Cancer Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population Yi-long Wu (2015)
Transl Lung Cancer Res Neoadjuvant and adjuvant epidermal growth factor receptor tyrosinekinase inhibitor (EGFR-TKI) therapy for lung cancer Yi-long Wu (2015)
Transl Lung Cancer Res Single nucleotide polymorphisms of MAGE-A3 gene and its clinical implications in Chinese patients with non-small cell lung cancer (NSCLC) Yi-long Wu (2015)
J Thorac Oncol Leptomeningeal metastases innon-small cell lung cancer patients with EGFR mutations Yi-long Wu (2016)
J Hematol Oncol Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial Yi-long Wu (2016)
J Thorac Oncol The unique characteristics of MET exon 14 mutation in Chinese non-small cell lung cancer patients Yi-long Wu(2016)
J Thorac Oncol A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R Yi-long Wu (2017)
Clin Cancer Res Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitorsin non-small cell lung cancer Yi-long Wu (2017)
J Thorac Oncol Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelicconfiguration at resistance Yi-long Wu (2017)
Clin Cancer Res Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor Cells Yi-long Wu (2017)
J Thorac Oncol Genetic and immune profiles of solid predominant lung adenocarcinoma reveal potential immunotherapeutic strategies Yi-long Wu (2017)
OncoImmunology EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer Yi-long Wu (2017)
J Thorac Oncol Osimertinib and cabozantinib combinatorial therapy in an EGFR-mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to crizotinib Yi-long Wu (2017)
Clin Cancer Res Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma Yi-long Wu (2017)
OncoImmunology PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells Yi-long Wu (2017)
Oncologist Mixed responses to systemic therapy revealed potential genetic heterogeneity and poor survival in patients with non-small cell lung cancer Yi-long Wu (2017)
J Thorac Oncol EGFR L792H and G796R: two novel mutations mediating resistance tothe third-generation EGFR Tyrosine Kinase Inhibitor Osimertinib Yi-long Wu(2018)
J Thorac Oncol Neoadjuvant Crizotinib in resectable locally advanced Non-small-cell lung cancer with ALK-rearrangement Yi-long Wu (2018)
J Thorac Oncol Stromal PD-L1+regulatory T cells and PD-1+CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy Yi-long Wu (2018)
J Thorac Oncol Strong Programmed Death Ligand 1 expression predicts poor responseand De Novo resistance to EGFR Tyrosine Kinase Inhibitors among NSCLC patients with EGFR mutation Yi-long Wu (2018)
Ann Oncol Uniquegenetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy Yi-long Wu (2018)
J Thorac Oncol Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for leptomeningeal metastases in ALK-rearranged NSCLC Yi-long Wu (2019)
J Extracell Vesicles Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules Yi-long Wu (2019)
J Thorac Oncol Genomic landscape and immune microenvironment features of preinvasive and early ienvasive lung adenocarcinoma Yi-long Wu (2019)
Oncologist Toward an expert level of lung cancer detection and classification using a deep convolutional neural network Yi-long Wu (2019)
Transl Lung Cancer Res TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer Yi-long Wu (2019)
Nat Commun Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients Yi-long Wu (2019)
JAMA Network Open Association of cerebrospinal fluid tumor DNA genotyping with survival among patients with lung adenocarcinoma and central nervous system metastases Yi-long Wu (2020)
J Immunother Cancer Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer Yi-long Wu (2020)
J Immunother Cancer Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study Yi-long Wu (2020)
J Thorac Oncol Real-world scenario of patients with lung cancer Amid the Coronavirus Disease 2019 pandemic in the People’s Republic of China Yi-long Wu (2020)
J Hematol Oncol Association of genetic and immunocharacteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study Yi-long Wu (2020)
J Thorac Oncol Real-world scenario of patients with lung cancer amid the coronavirus disease 2019 Pandemic in the People’s Republic of China Yi-long Wu (2020)
EBioMedicine Specific TP53 subtype as biomarker for immune checkpoint inhibitorsin lung adenocarcinoma Yi-long Wu (2020)